Novel Psychoactive Substances and legislative harmonization in Europe: addressing a extremely elusive public health threat.
作者信息
Umani Ronchi Federica
机构信息
Department of Anatomical, Histological, Medicolegal and Orthopedic Sciences, University of Rome "Sapienza", Rome, Italy.
出版信息
Acta Biomed. 2023 Feb 13;94(1):e2023005. doi: 10.23750/abm.v94i1.14194.
Abstract
摘要
相似文献
1
Novel Psychoactive Substances and legislative harmonization in Europe: addressing a extremely elusive public health threat.新型精神活性物质与欧洲的立法协调：应对极其难以捉摸的公共卫生威胁。
Acta Biomed. 2023 Feb 13;94(1):e2023005. doi: 10.23750/abm.v94i1.14194.
2
New psychoactive substances: concerted efforts and common legislative answers for stemming a growing health hazard.新精神活性物质：协调努力和共同立法对策遏制日益严重的健康危害。
Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):9681-9690. doi: 10.26355/eurrev_201911_19529.
3
Monitoring psychoactive substance use at six European festivals through wastewater and pooled urine analysis.通过污水和混合尿液分析监测六个欧洲节日中的精神活性物质使用情况。
Sci Total Environ. 2020 Jul 10;725:138376. doi: 10.1016/j.scitotenv.2020.138376. Epub 2020 Apr 3.
4
How preclinical studies have influenced novel psychoactive substance legislation in the UK and Europe.临床前研究如何影响英国和欧洲的新型精神活性物质立法。
Br J Clin Pharmacol. 2020 Mar;86(3):452-481. doi: 10.1111/bcp.14224. Epub 2020 Feb 23.
5
New Psychoactive Substances: Evolution in the Exchange of Information and Innovative Legal Responses in the European Union.新型精神活性物质：欧盟信息交流和创新法律应对的演变。
Int J Environ Res Public Health. 2020 Nov 23;17(22):8704. doi: 10.3390/ijerph17228704.
6
[Use of synthetic substances in France and in Europe].[法国及欧洲合成物质的使用情况]
Therapie. 2021 May-Jun;76(3):221-228. doi: 10.1016/j.therap.2020.07.005. Epub 2020 Jul 15.
7
A systematic review of the effects of novel psychoactive substances 'legal highs' on people with severe mental illness.新型精神活性物质“合法兴奋剂”对重症精神疾病患者影响的系统评价
J Psychiatr Ment Health Nurs. 2016 Jun;23(5):267-81. doi: 10.1111/jpm.12297. Epub 2016 Apr 1.
8
New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe.新型精神活性物质：欧洲应对其使用及危害的当前健康相关做法与挑战
Int J Drug Policy. 2017 Feb;40:84-92. doi: 10.1016/j.drugpo.2016.10.004. Epub 2016 Dec 9.
9
The challenge of complex drug use: Associated use of codeine-containing medicines and new psychoactive substances in a European cross-sectional online population.复杂药物使用的挑战：欧洲在线横断面人群中含可待因药物与新型精神活性物质的联合使用
Hum Psychopharmacol. 2017 May;32(3). doi: 10.1002/hup.2611. Epub 2017 Jun 9.
10
Monitoring novel psychoactive substances allegedly offered online for sale in Persian and Arabic languages.监测据称在波斯语和阿拉伯语网络上提供销售的新型精神活性物质。
Int J Drug Policy. 2014 Jul;25(4):724-6. doi: 10.1016/j.drugpo.2014.05.005. Epub 2014 May 22.
本文引用的文献
1
The effects of the COVID-19 pandemic on the use of the performance-enhancing drugs.COVID-19 大流行对使用兴奋剂的影响。
Acta Biomed. 2022 Jan 19;92(6):e2021401. doi: 10.23750/abm.v92i6.12377.
2
Development and validation of fast UHPLC-MS/MS screening method for 87 NPS and 32 other drugs of abuse in hair and nails: application to real cases.建立并验证一种快速 UHPLC-MS/MS 筛选方法，用于检测毛发和指甲中的 87 种新型精神活性物质和 32 种其他滥用药物：实际案例应用。
Anal Bioanal Chem. 2020 Aug;412(21):5125-5145. doi: 10.1007/s00216-020-02462-6. Epub 2020 Feb 15.
3
Sex enhancers: challenges, threats and the need for targeted measures.性增强剂：挑战、威胁及采取针对性措施的必要性。
Clin Ter. 2019 May-Jun;170(3):e181-e183. doi: 10.7417/CT.2019.2130.
4
Is GHB-glucuronide useful as a biomarker for the exogenous use of GHB?γ-羟基丁酸葡萄糖醛酸苷能否作为γ-羟基丁酸外用的生物标志物？
Eur Rev Med Pharmacol Sci. 2019 Mar;23(6):2311-2313. doi: 10.26355/eurrev_201903_17369.
Zotero 插件